MedTrace Logo

Phase 0/1 Study of 212Pb-NG001 in mCRPC

NCT05725070 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 3

Last updated 2023-10-06

No results posted yet for this study

Summary

The purpose of this study is to evaluate the imaging feasibility and safety of 212Pb-NG001.

Conditions

Interventions

DRUG

212Pb-NG001

212Pb-NG001 is a targeted alpha-emitting radiopharmaceutical conjugated to a PSMA targeting peptide. Patients will receive an initial single 10 MBq dose IV to explore the imaging potential of 212Pb-NG001.

Sponsors & Collaborators

  • ARTBIO Inc.

    lead INDUSTRY

Principal Investigators

  • Kjetil Berner, MD · Oslo University Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-06
Primary Completion
2023-07-06
Completion
2023-07-06

Countries

  • Norway

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05725070 on ClinicalTrials.gov